SETD2 and nonpapillary renal cell carcinoma: Referenced by cBioPortal database and reported research (31, 32, 34, 36–38, 42), SETD2 mutations were identified in ccRCC predominantly inactivating, containing nonsense mutations, missense mutations, frame shift, and fusion, which lead to loss of function, such as mutations R1625C or R1625G, resulting in a complete loss of SETD2 enzymatic activity (31, 33) (Table 1).